Aviva PLC Sells 12,300 Shares of Solventum Co. (NYSE:SOLV)

Aviva PLC trimmed its position in Solventum Co. (NYSE:SOLV - Free Report) by 12.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 82,853 shares of the company's stock after selling 12,300 shares during the period. Aviva PLC's holdings in Solventum were worth $5,473,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of SOLV. Vanguard Group Inc. increased its position in Solventum by 0.5% during the 4th quarter. Vanguard Group Inc. now owns 16,266,893 shares of the company's stock valued at $1,074,591,000 after purchasing an additional 75,631 shares during the period. Geode Capital Management LLC increased its position in shares of Solventum by 3.4% during the fourth quarter. Geode Capital Management LLC now owns 3,460,405 shares of the company's stock worth $227,992,000 after buying an additional 112,686 shares during the period. Norges Bank acquired a new stake in shares of Solventum during the fourth quarter worth $203,740,000. Boston Partners bought a new position in Solventum during the fourth quarter worth $110,378,000. Finally, Arrowstreet Capital Limited Partnership boosted its position in Solventum by 41.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,193,361 shares of the company's stock valued at $78,833,000 after acquiring an additional 347,669 shares during the last quarter.

Solventum Price Performance

Shares of NYSE SOLV traded down $1.05 during midday trading on Tuesday, hitting $66.76. 174,604 shares of the company's stock were exchanged, compared to its average volume of 1,333,381. The business's fifty day moving average price is $74.05 and its two-hundred day moving average price is $71.73. The company has a market cap of $11.55 billion and a price-to-earnings ratio of 24.27. Solventum Co. has a 12-month low of $47.16 and a 12-month high of $85.92. The company has a current ratio of 1.15, a quick ratio of 0.83 and a debt-to-equity ratio of 2.45.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. The Goldman Sachs Group raised their target price on Solventum from $63.00 to $71.00 and gave the stock a "sell" rating in a research note on Monday, March 3rd. Bank of America lifted their price objective on shares of Solventum from $80.00 to $85.00 and gave the company a "neutral" rating in a research note on Wednesday, February 26th. Piper Sandler increased their target price on shares of Solventum from $75.00 to $84.00 and gave the stock a "neutral" rating in a research note on Friday, February 28th. Morgan Stanley lifted their price target on shares of Solventum from $73.00 to $80.00 and gave the company an "equal weight" rating in a research note on Wednesday, March 5th. Finally, Mizuho increased their price objective on shares of Solventum from $70.00 to $82.00 and gave the stock a "neutral" rating in a research report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and one has issued a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $79.86.

Solventum Company Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.